Concepedia

Bijoyesh Mookerjee

BM

Statistics

Publications

58

Citations

14.2K

H-Index

37

Active since

1992

Affiliations

Institut Gustave Roussy(Current)

Novartis (United States)

Novartis (Switzerland)

Aix-Marseille Université

The University of Texas MD Anderson Cancer Center

Bijoyesh Mookerjee is an author at Institut Gustave Roussy specializing in oncology, medicine, and molecular oncology.

Publications per year

1992–2024

58

Publications

58

Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma

Georgina V. Long, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2017 · 1.5K citations · Full text

, , +17

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas et al. · The Lancet · 2015 · 1.4K citations

, , +7

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard, Egbert F. Smit, Harry J.M. Groen et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

, , +11

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Rajani Ravi, Bijoyesh Mookerjee, Zaver M. Bhujwalla et al. · PubMed · 2000 · 1.1K citations · Full text

, , +17

Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α

Rajani Ravi, Bijoyesh Mookerjee, Zaver M. Bhujwalla et al. · Genes & Development · 2000 · 958 citations · Full text

, , +17

1–5 of 58